These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

206 related items for PubMed ID: 34320885

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Treatment patterns for biologics in ulcerative colitis and Crohn's disease: a Danish Nationwide Register Study from 2003 to 2015.
    Alulis S, Vadstrup K, Borsi A, Nielsen A, Rikke Jørgensen T, Qvist N, Munkholm P.
    Scand J Gastroenterol; 2020 Mar; 55(3):265-271. PubMed ID: 32116064
    [Abstract] [Full Text] [Related]

  • 3. Biologic Use Patterns and Predictors for Non-persistence and Switching of Biologics in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Study.
    Jung YS, Han M, Park S, Cheon JH.
    Dig Dis Sci; 2020 May; 65(5):1436-1444. PubMed ID: 31677070
    [Abstract] [Full Text] [Related]

  • 4. Drug utilization of biologic therapy in Crohn's disease and ulcerative colitis: a population-based Danish cohort study 2015-2020.
    Jensen KJ, Jensen CB, Wennerström C, Burisch J, Petersen J.
    Scand J Gastroenterol; 2023 Jul; 58(7):726-736. PubMed ID: 36802972
    [Abstract] [Full Text] [Related]

  • 5. Real-World Persistence of Successive Biologics in Patients With Inflammatory Bowel Disease: Findings From ROTARY.
    Krugliak Cleveland N, Ghosh S, Chastek B, Bancroft T, Candela N, Fan T, Umashankar K, Rubin DT.
    Inflamm Bowel Dis; 2024 Oct 03; 30(10):1776-1787. PubMed ID: 37921344
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The cost burden of Crohn's disease and ulcerative colitis depending on biologic treatment status - a Danish register-based study.
    Alulis S, Vadstrup K, Olsen J, Jørgensen TR, Qvist N, Munkholm P, Borsi A.
    BMC Health Serv Res; 2021 Aug 18; 21(1):836. PubMed ID: 34407821
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Real-World Treatment Patterns and Physician Preferences for Biologics in Moderate-to-Severe Inflammatory Bowel Disease: Retrospective Chart Review in Europe.
    Huynh L, Hass S, Peyrin-Biroulet L, Duh MS, Sipsma H, Cheng M, Lax A, Nag A.
    Crohns Colitis 360; 2022 Jan 18; 4(1):otac001. PubMed ID: 36777550
    [Abstract] [Full Text] [Related]

  • 11. Biosimilars in inflammatory bowel disease.
    Talathi S, Baig KRKK.
    J Dig Dis; 2020 Nov 18; 21(11):610-620. PubMed ID: 32920972
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of biosimilar versus originator infliximab in patients with inflammatory bowel disease: A real-world cohort analysis.
    Kumar P, Vuyyuru SK, Kante B, Kedia S, Sahu P, Ranjan MK, Mundhra S, Golla R, Kumar M, Virmani S, Gupta A, Yadav N, Makharia G, Ahuja V.
    Indian J Gastroenterol; 2022 Oct 18; 41(5):446-455. PubMed ID: 36378484
    [Abstract] [Full Text] [Related]

  • 13. The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization.
    Kuenzig ME, Benchimol EI, Lee L, Targownik LE, Singh H, Kaplan GG, Bernstein CN, Bitton A, Nguyen GC, Lee K, Cooke-Lauder J, Murthy SK.
    J Can Assoc Gastroenterol; 2019 Feb 18; 2(Suppl 1):S17-S33. PubMed ID: 31294382
    [Abstract] [Full Text] [Related]

  • 14. Racial or ethnic differences on treatment adherence and persistence among patients with inflammatory bowel diseases initiated with biologic therapies.
    Cai Q, Ding Z, Fu AZ, Patel AA.
    BMC Gastroenterol; 2022 Dec 29; 22(1):545. PubMed ID: 36581802
    [Abstract] [Full Text] [Related]

  • 15. Healthcare resource utilization and treatment costs of Finnish chronic inflammatory bowel disease patients treated with infliximab.
    Ylisaukko-Oja T, Torvinen S, Ventola H, Schmidt S, Herrala S, Kononoff J, Voutilainen M.
    Scand J Gastroenterol; 2019 Jun 29; 54(6):726-732. PubMed ID: 31203693
    [Abstract] [Full Text] [Related]

  • 16. Treatment and biologic maintenance-dosing patterns among pediatric patients with ulcerative colitis or Crohn's disease.
    Hunter T, Komocsar WJ, Colletti RB, Liu C, Benkov KJ, Dotson JL, Steiner SJ, Zhang N, Crandall W, ImproveCareNow Network.
    Curr Med Res Opin; 2023 Jan 29; 39(1):63-69. PubMed ID: 36263735
    [Abstract] [Full Text] [Related]

  • 17. Real-World Persistence of Ustekinumab in the Treatment of Inflammatory Bowel Disease.
    Bressler B, Jones J, In TSH, Lan T, Iconaru C, Marshall JK.
    Adv Ther; 2023 Oct 29; 40(10):4421-4439. PubMed ID: 37507652
    [Abstract] [Full Text] [Related]

  • 18. Infliximab biosimilar CT-P13 therapy is effective and safe in maintaining remission in Crohn's disease and ulcerative colitis - experiences from a single center.
    Farkas K, Rutka M, Ferenci T, Nagy F, Bálint A, Bor R, Milassin Á, Fábián A, Szántó K, Végh Z, Kürti Z, Lakatos PL, Szepes Z, Molnár T.
    Expert Opin Biol Ther; 2017 Nov 29; 17(11):1325-1332. PubMed ID: 28819991
    [Abstract] [Full Text] [Related]

  • 19. Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study.
    Tursi A, Mocci G, Allegretta L, Aragona G, Bianco MA, Colucci R, Cuomo A, Della Valle N, Ferronato A, Forti G, Gaiani F, Giorgetti G, Graziani MG, Lofano K, Lorenzetti R, Larussa T, Penna A, Pica R, Pranzo G, Rodino' S, Scarcelli A, Zampaletta C, Bassotti G, Cazzato AI, Chiri S, Clemente V, Cocco A, De' Angelis G, Donnarumma L, Faggiani R, Graziosi C, Le Grazie M, Luzza F, Meucci C, Monterubbianesi R, Pagnini C, Perazzo P, Picchio M, Sacco R, Sebkova L, Serio M, Napolitano D, Pugliese D, Scaldaferri F, Schiavoni E, Turchini L, Armuzzi A, Elisei W, Maconi G, Papa A.
    Inflamm Bowel Dis; 2023 Mar 01; 29(3):376-383. PubMed ID: 35579320
    [Abstract] [Full Text] [Related]

  • 20. Rates of Intestinal Resection and Colectomy in Inflammatory Bowel Disease Patients After Initiation of Biologics: A Cohort Study.
    Khoudari G, Mansoor E, Click B, Alkhayyat M, Saleh MA, Sinh P, Katz J, Cooper GS, Regueiro M.
    Clin Gastroenterol Hepatol; 2022 May 01; 20(5):e974-e983. PubMed ID: 33065311
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.